Update: Actavis and Allergan leaders discuss merger deal

Article

Actavis CEO Brent Saunders and Allergan CEO David Pyott discuss the recent acquisition deal between the two companies with industry media.

Actavis CEO Brent Saunders and Allergan CEO David Pyott discuss the recent acquisition deal between the two companies with industry media.

“The combined companies will have pro forma of revenue of about $23 billion dollars in 2015, and we’ll be a leader in categories like ophthalmology, medical aesthetics, neurology, gastrointestinal, and women’s health among other areas,” says Saunders. “We’re excited about creating one of the fastest-growing, most dynamic pharmaceutical companies in the world.”

Listen to the full interview with sister publication Ophthalmology Times.

When Actavis acquired Allergan for approximately $66 billion, Allergan avoided a hostile takeover from Valeant Pharmaceuticals.

“I decided it was far better to enter into a negotiation where we would look at selling for a fair value. It’s clear that Valeant’s goal was to steal this company at a ridiculously low price,” Pyott told Optometry Times.

When the pair spoke with us shortly after the deal in November, they both remained optimistic about the combined company’s future and its vision for eye care.

Check out our original story here.

Recent Videos
Walline, OD, PhD, FAAO, outlines how to predict myopia progression and delay its onset in an exclusive interview with Optometry Times.
Jeffrey Walline, OD, PhD, FAAO, overviews a presentation he gave on the Bifocal Lenses in Nearsighted Kids 2 (BLINK2) cohort study at the Collaborative Community on Ophthalmic Innovation (CCOI).
Danica Marrelli, OD, FAAO, at Glaucoma 360 discussing visual field testing for patients with glaucoma
Walline, OD, PhD, FAAO, states that the best way to learn the benefits of artificial intelligence for your practice is to stay on top of continuing education attendance.
Jeffrey Walline, OD, PhD, FAAO, gives an overview of the AAO's 2024 and what to expect in 2025 and beyond.
Dr Jamie Kuzniar discusses higher order aberrations and premium scleral lenses
Abby Gillogly Harsch, OD, FAAO, FSLS, shares a specific complex case of scleral lens fitting that she presented on at this year's GSLS.
Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.
© 2025 MJH Life Sciences

All rights reserved.